BANGKOK—Thailand’s health minister helped plant cannabis seedlings on Thursday as the government nurtures plans to harvest the multibillion-dollar potential of medical marijuana.
The kingdom in 2018 became the first country in Southeast Asia to legalize medical marijuana, although many Thais have long used the herb in traditional treatments.
The government has invested in the extraction, distillation, and marketing of cannabis oils for use in the health industry.
Wearing a hairnet and green gardening gloves, Deputy Prime Minister Anutin Charnvirakul joined health officials planting seedlings at Thailand’s second industrial-scale marijuana greenhouse at Nong Yai, Chonburi province.
In a statement, Anutin said the administration wanted to “support with sincerity patients who need to use cannabis for treatment.”
Thailand’s Health Minister Anutin Charnvirakul holds a cannabis seedling during a planting ceremony at the Government Pharmaceuticals Organisation (GPO) medicinal marijuana greenhouse outside Chon Buri, south of Bangkok on October 8, 2020. (Photo by Mladen ANTONOV / AFP)
Broaden laws
The Government Pharmaceutical Organization’s 1,550-square-meter facility will house 1,300 plants supplying marijuana products to hospitals and clinics.
The government wants to further broaden Thailand’s laws on cultivating cannabis.
A bill is expected to go before parliament in the coming weeks which would allow individuals to grow the plant for medicinal purposes—something only state agencies can do currently.
The minister said he hoped the changes could boost rural incomes across the northeast by allowing farmers to grow and sell the plants.
Medical research has shown cannabis oil can help ease chronic pain and conditions, such as multiple sclerosis and epilepsy.
Recreational use and trade of marijuana in Thailand is still illegal, however, and convictions carry up to 10 years in prison.
Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.
